Lifecore Biomedical Inc (LFCR)
4.95
+0.23
(+4.87%)
USD |
NASDAQ |
Sep 27, 16:00
4.93
-0.02
(-0.40%)
After-Hours: 20:00
Lifecore Biomedical Research and Development Expense (Annual): 8.575M for May 31, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| May 31, 2024 | 8.575M |
| May 31, 2023 | 8.736M |
| May 31, 2022 | 7.839M |
| May 31, 2021 | 6.684M |
| May 31, 2020 | 7.582M |
| May 31, 2019 | 11.47M |
| May 31, 2018 | 12.80M |
| May 31, 2017 | 9.473M |
| May 31, 2016 | 7.228M |
| May 31, 2015 | 6.988M |
| May 31, 2014 | 7.204M |
| May 31, 2013 | 9.294M |
| May 31, 2012 | 9.625M |
| May 31, 2011 | 9.275M |
| May 31, 2010 | 4.361M |
| Date | Value |
|---|---|
| May 31, 2009 | 3.665M |
| May 31, 2008 | 3.251M |
| May 31, 2007 | 3.074M |
| May 31, 2006 | 3.042M |
| May 31, 2005 | 2.543M |
| May 31, 2004 | 3.452M |
| May 31, 2003 | 2.118M |
| October 31, 2002 | 3.664M |
| October 31, 2001 | 3.27M |
| October 31, 2000 | 3.444M |
| October 31, 1999 | 4.653M |
| October 31, 1998 | 5.70M |
| October 31, 1997 | 7.60M |
| October 31, 1996 | 3.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
6.684M
Minimum
2021
8.736M
Maximum
2023
7.883M
Average
7.839M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Ligand Pharmaceuticals Inc | 24.54M |
| Sage Therapeutics Inc | 356.24M |
| Outset Medical Inc | 57.31M |
| Anebulo Pharmaceuticals Inc | 3.549M |
| NovaBay Pharmaceuticals Inc | 0.068M |